FDA label e704d5a7-9db0-4f0f-8267-7ea92d8d882e
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- b3f69e25-1b87-4507-81fa-582ea084673d
- SPL ID
- e704d5a7-9db0-4f0f-8267-7ea92d8d882e
- Version
- 9
- Effective date
- 2025-09-30
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:30
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | e704d5a7-9db0-4f0f-8267-7ea92d8d882e | id | |
| spl set id | b3f69e25-1b87-4507-81fa-582ea084673d | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions: TISSEEL contains aprotinin, a protein known to be associated with anaphylactic reactions. ( 5.1 , 6.2 ) • Air or Gas Embolism: To reduce the risk of potential life-threatening gas embolism, spray using only the appropriate pressurized gas at the recommended pressure and distance. For Open Surgical procedures, use the EASYSPRAY device connected to CO 2 , Medical Air or Nitrogen. For Minimally Invasive Surgery procedures use the DUPLOSPRAY MIS device connected only to CO 2 . ( 5.2 ) • TISSEEL may be denatured when exposed to solutions containing alcohol, iodine or heavy metals. ( 5.2 ) • Use in Surgery: When using TISSEEL in surgery do not inject intravascularly. ( 4 , 5.3 , 6.2 ) • Neurosurgical Procedures: Safety has not been evaluated in neurosurgical procedures. ( 5.4 ) • Transmission of Infectious Agents: TISSEEL is made from pooled human plasma and may carry a risk of transmitting infectious agents. ( 5.4 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with the use of TISSEEL [ see Adverse Reactions (6.2 )]. Aprotinin included in TISSEEL for its antifibrinolytic properties is associated with hypersensitivity including anaphylactic reactions. Patients who receive repeated applications of TISSEEL over time or in the same setting, or who previously received systemic aprotinin are at a higher risk for hypersensitivity reactions. Hypersensitivity reactions may occur with initial or subsequent applications of TISSEEL. Document the use of TISSEEL in the patient's records, noting that TISSEEL contains aprotinin, as required for all aprotinin-containing products. Monitor patients for signs and symptoms of hypersensitivity reactions which include bradycardia, tachycardia, hypotension, flushing, bronchospasm, wheezing, dyspnea, nausea, urticaria, angioedema, pruritus, erythema and paresthesia. Discontinue administration of TISSEEL in the event of hypersensitivity reactions and manage according to clinical practice. Remove remaining product from the application site. 5.2 Air or Gas Embolism Life threatening or fatal air or gas embolism, tissue rupture or gas entrapment with compression, have occurred when Fibrin Sealants were administered using pressurized gas with open regulator spray devices [ see Adverse Reactions (6)]. This can occur if a spray device is used at higher than recommended pressures and in closer than recommended proximity to the tissue surface. The solubility of compressed CO 2 is greater than either compressed N 2 or Air thereby reducing the potential effect of embolization. Regardless of the type of gas used, to reduce the incidence of embolization, spray TISSEEL using only the recommended regulator, set within the recommended pressure range, with the appropriate applicator positioned at the recommended distance in Table 5. Monitor changes in blood pressure, pulse, oxygen saturation and end tidal CO 2 due to the possibility of air or gas embolism. Use only spray catheters or applicators approved for use with TISSEEL. Do not spray TISSEEL in enclosed body areas using the EASYSPRAY device. Spray only on the visible application sites. For Open Surgical Procedures , use the EASYSPRAY Pressure Regulator connected to medical grade CO 2 , compressed Air or a Nitrogen compressed gas source along with the TISSEEL/ARTISS spray set ( see Method of Application (2.4 ) ). For Minimally Invasive Surgery Procedures in enclosed body areas use of the DUPLOSPRAY MIS device connected only to compressed CO 2 , along with DUPLOSPRAY applicator is recommended. The DUPLOSPRAY MIS device is specifically designed to prevent over pressurization of the body cavity through a dedicated ventline to reduce the risk of gas embolization, ( see Method of Application (2.4)). The Sealer Protein and Thrombin solutions may be denatured by alcohol, iodine or heavy metal ions. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL. 5.3 Use in Surgery When using TISSEEL in surgery, do not inject intravascularly ( see Contraindications (4) and Adverse Reactions (6.2) ). 5.4 Use in Neurosurgical Procedures The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated, and its use in this setting is not approved by FDA (see Adverse Reactions (6.2 ) and Drug Interactions (7) ). 5.5 Transmission of Infectious Agents TISSEEL is made from human blood, therefore it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically the Creutzfeldt-Jakob disease (CJD) agent. All infections thought possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Baxter Healthcare Corporation at 1-888-229-0001.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Most common adverse reaction include hypersensitivity including anaphylactic reaction and anaphylactic shock. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-888-229-0001 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflects exposure of TISSEEL in five clinical trials, Study 1, Study 2, Study 3, Study 4, and Study 5. A total of 452 patients received TISSEEL as an adjunct to hemostasis undergoing surgery when control of bleeding by conventional surgical techniques is ineffective or impractical in Study 1, Study 2, Study 3, and Study 4, or for sealing as an adjunct to standard surgical technique to prevent leakage from colonic anastomoses following the reversal of temporary colostomies in Study 5. The mean volume of TISSEEL applied was 5.3 mL (range 0.2 – 20.0 mL). The follow up duration for Study 1 was 30 days. The follow up duration for Study 2 and Study 3 was 6 months. The follow up duration for Study 4 was a maximum of 167 days. The follow up duration for Study 5 was a maximum of 69 days ( see Clinical Studies (14 )). Increased D-Dimer levels have been observed during a clinical study in cardiovascular surgery ( see Clinical Studies (14)), but did not exceed values reported in the literature occurring after this type of surgery. Postoperatively increased D-Dimers can result at least partly from the degradation of Fibrin Sealant. There were no reports of serious, associated adverse reactions reported above 1% in clinical studies. 6.2 Post-Marketing Experience Because adverse reactions are reported voluntarily and the population is of uncertain size, it is not always possible to reliably estimate the frequency of these reactions. The following adverse reactions have been reported in the post-marketing experience. Immune System Disorders: Hypersensitivity, including anaphylactic reaction and anaphylactic shock. Anaphylactic reactions and anaphylactic shock have included fatal outcomes. Vascular Disorders: Hypotension, flushing, embolism, including cerebral artery embolism, cerebral infarction*, air embolism** Skin and subcutaneous Tissue Disorders: Angioedema, erythema, impaired healing, pruritus, urticaria Cardiac Disorders: Bradycardia, tachycardia Respiratory Disorders : Bronchospasm, dyspnea, wheezing Gastrointestinal Disorders: Nausea Nervous System Disorders: Paresthesia * As a result of intravascular application into the superior petrosal sinus ** As with other fibrin sealants life-threatening/fatal air or gas embolism when using devices with pressurized air or gas occurred; this event appears to be related to an inappropriate use of the spray device (e.g. at higher than recommended pressure and in close proximity to the tissue surface), Class effect: Manifestations of hypersensitivity or allergic reactions associated with the class of fibrin sealant/hemostatic products include: application site irritation, chest discomfort, chills, headache, lethargy, restlessness and vomiting. There have been reports of serious adverse events such as paralysis and other compressive complications possibly related to the use of fibrin sealants in combination with resorbable hemostatic agents. There have also been reports of fatalities following the misadministration of topical thrombin (see Warnings and Precautions (5.4) ).
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.